Surgical cost per patient for Eustachian tube surgery is about $15,000. $15,000/patient * 430,000 patients/year = $6.4 Bil/year, leading to a Total Addressable Market (TAM) of $6.4 Billion. However, our patient focus is only on US adult cases. Children’s ET anatomy changes adding undue design challenges. With the US population being 77% adults, the Serviceable Addressable Market (SAM) is limited to $4.9 Billion. Finally, we propose our solution can capture 30% of the SAM leading to a Serviceable Obtainable Market (SOM) of $1.5B. Thirty percent is an aggressive portion of the market to capture but it is attainable due to the lack of current standards of care.

Current solutions available to providers prove difficult to implement which leads to long surgical times at high costs. The solution proposed will be performed under general anesthesia but will utilize techniques that physicians are already familiar with such as endoscopy and catheters, thus decreasing OR time and physician training. Non-surgical implants and treatments can inhibit pressure equalization and will typically need to be replaced within one year. In contrast, the valve-in-stent device provides natural pressure relief and sound dampening 10 years.